Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling

Executive Summary

An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny

You may also be interested in...



FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf

In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.

"Bad CME" Program May Be Developed By FDA

Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.

DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows

Amgen rep's description of KRAS information as predictive of response to the colorectal cancer drug during a ASHP meeting draws a notice of violation from FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS052414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel